Alison Mcvie-Wylie, PhD

Title: Vice President, Disease Area Executive, DMD

Organization: Vertex Pharmaceutical

Bio: Alison McVie-Wylie is the Vice President, Disease Area Executive, Duchenne Muscular Dystrophy at Vertex. Prior to Vertex, Alison led Preclinical Development at Exonics Therapeutics and served as the Head of Rare Disease Gene Therapy and Biologics Pharmacology at Sanofi-Genzyme. Alison was the lead Scientist responsible for the nonclinical development of Myozyme from early concept to marketing approval. Alison obtained her Ph.D. in Molecular Genetics from the University of Glasgow, Scotland.

2021 FUTURES: Gene Therapy & Gene Editing Symposium

Information and updates on the gene therapy and gene editing landscape from experts in the field.

**We experienced a technical issue during this session. Please reach out with questions to Futures@CureDuchenne.org if needed.

Beth Belluscio, MD, PhD

Global Clinical Lead, Rare Neurological Disorders

Pfizer

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

Eric Olson, PhD

Chief Scientific Advisor

Vertex Pharmaceuticals

Matthew Pletcher, PhD

Division Head of Gene Therapy Research & Technical Operations

Astellas Gene Therapies

Deanna Tucker

Senior Medical Science Liaison

Sarepta Therapeutics

Genine Winslow, MSc

CEO & President

Chameleon Biosciences